.jpeg)
Syngene International shares are expected to be in focus after two major regulatory statements by the United States Food and Drug Administration (USFDA) on inspections at the company's Bengaluru-based facilities.
.jpeg)
Bayer has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for gadoquatrane, the firm's investigational gadolinium-based contrast agent for use in contrast-enhanced CNS and other body region MRI.
Boehringer Ingelheim, a global leader in animal health, has announced the launch of its latest poultry vaccine in India—a single-dose, next-generation solution that provides protection against Bursal, Newcastle and Marek’s disease...
In a significant step toward strengthening India’s pharmaceutical and trade export ecosystem, the Directorate General of Foreign Trade (DGFT), Ministry of Commerce and Industry, has announced the launch of the ‘Source from India’ feature...
The Department of Pharmaceuticals (DoP) has clarified that they extended the application period for the most recent PLI scheme round for bulk drugs, from June 14 to July 4, 2025...
Johnson & Johnson reported positive results from a Phase 2 study of the combination of Talvey (talquetamab-tgvs) and Tecvayli (teclistamab-cqyv)—both bispecific antibodies that have been...
Eli Lilly announced its acquisition of gene-editing startup Verve Therapeutics in a deal with up to a potential of $1.3 billion, expanding its pipeline, which now also features weight-loss medications and its blockbuster diabetes drugs...
The launch of Samsung Organoids, which is a advanced drug screening services to support clients in drug discovery and development was announced by Samsung Biologics, a leading contract development and manufacturing organization
.jpeg)
The Smt. Anupriya Patel, Union Minister of State for Health & Family Welfare and Chemicals & Fertilizers, provided a note to address at the Second Policymakers’ Forum, organized by the Indian Pharmacopoeia Commission
.jpeg)
Roche has reported it will move prsazinezumab, its investigational anti-alpha-synuclein antibody, into Phase III development for early-stage Parkinson’s disease following an assessment
, CDSCO.jpg)
